Novavax, Inc. Reports Progress on RSV Vaccine at the XV International Symposium on Respiratory Viral Infections

Published: Mar 18, 2013

ROCKVILLE, Md., March 18, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) reported that David C. Flyer, Ph.D., Director of Preclinical Development at Novavax, presented recent preclinical findings from the company's respiratory syncytial virus (RSV) vaccine development program at the XV International Symposium on Respiratory Viral Infections in Rotterdam, the Netherlands. He reported that in preclinical studies, Novavax' RSV vaccine candidate induced anti-RSV antibodies capable of neutralizing RSV in vitro and significantly reduced infectious RSV in a cotton rat challenge model. Further, in both clinical and preclinical studies, he reported that palivizumab-competing antibodies were generated at titers significantly above that found to be protective in both humans and cottons rats.

Back to news